PTC Therapeutics announced that the FDA has accepted for filing the Biologics License Application for Upstaza, a gene therapy for the treatment of AADC deficiency. The application has been granted Priority Review with a target regulatory action date of November 13, 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics upgraded to Equal Weight from Underweight at Morgan Stanley
- PTC Therapeutics price target raised to $18 from $17 at Citi
- PTC Therapeutics Q1 Financial Results Conference Call
- PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- PTC Therapeutics backs FY24 revenue view $600M-$680B, consensus $606.63M